- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04406129
Effect of Gut Microbiome Restoration on Primary Hypertension Via FMT (FMT)
Effect of Fecal Microbiota Transplantation on Primary Hypertension and the Underlying Mechanism of Gut Microbiome Restoration: a Randomized Clinical Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Primary hypertension is a most prevalent cardiovascular diseases, and becomes a severe global public health issue because of the high morbidity and potential risk to other cardiovascular diseases. Several animal studies and diverse patient cohorts reported that the disorder of gut microbiome correlated with hypertension. Based on the investigators' previous work findings of metagenomics analysis, fecal transplantation and metabolomics changes in hypertension and pre-hypertension patients, a casual role of gut microbiome disorder was observed in primary hypertension and raised a hypothesis that gut microbiome restoration can be a potential approach to ameliorate hypertension. Recent studies indicated FMT, prebiotics, probiotics, dietary changes and other methodologies can assist gut microbiome restoration in diseases such as type 2 diabetes. The investigators therefore develop two pilot studies respectively utilizing FMT capsules (Pilot Study I) and innovative dietary changes (Pilot Study II) to explore the effect, safety and underlying mechanisms of gut microbiome restoration on hypertension. These pilot studies also present as the clinical translational section of the research project "The Role of Gut Microbiome in the Pathogenesis of Essential Hypertension"(Project ID 81630014, sponsored by National Natural Science Foundation of China).
This study is the Study I:
Objective: To explore the effect, safety and underlying mechanisms of gut microbiome restoration via FMT on primary hypertension.
Study Design: A multicenter, randomized, double-blinded, placebo-controlled pilot study.
Data quality control and statistical analysis: The investigators have invited professional statistic analysts to assist analyzing data and a third party to supervise data quality.
Ethics: The Ethics Committee of Fuwai Hospital approved this study. Informed consents before patient enrollment are required.
Study Type
Enrollment (Anticipated)
Phase
- Early Phase 1
Contacts and Locations
Study Contact
- Name: LUYUN FAN
- Phone Number: 01088392165
- Email: fuwai_fanluyun@163.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100037
- Not yet recruiting
- Fuwai Hospital, Chinese Academy of Medical Sciences
-
-
Guangdong
-
Shantou, Guangdong, China
- Recruiting
- The Second Affiliated Hospital of Shantou University
-
-
Shandong
-
Jinan, Shandong, China
- Recruiting
- Qilu Hospital of Shandong University
-
Contact:
- Peili Bu
-
-
Shanxi
-
Taiyuan, Shanxi, China
- Recruiting
- Shanxi Bethune Hospital
-
-
Shenzhen
-
Shenzhen, Shenzhen, China
- Recruiting
- Southern University of Science and Technology Hospital
-
Contact:
- Bingpo Zhu
-
-
Tianjin
-
Tianjin, Tianjin, China
- Not yet recruiting
- The People's Hospital of Ji Xian District
-
-
Yunnan
-
Kunming, Yunnan, China
- Recruiting
- Fuwai Yunnan Cardiovascular Hospital
-
Contact:
- Zihong Guo
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 18~60 years.
- Established Diagnosis of Grade 1 Hypertension (initial diagnosis or free from antihypertensive drugs within a month): 140mmHg≤ Office SBP<160mmHg for three measurements at different days without any antihypertensive medications, according to the "2010 Chinese Guidelines for Prevention and Treatment of Hypertension".
- Patients with informed consent after thorough explanation.
Exclusion Criteria:
- Antibiotics or probiotics usage within last 4 weeks
- Participants of other clinical trials related to hypertension currently or within last 3 months
- Antihypertensive medications usage currently or within last month
- Diagnosed secondary hypertension
- Severe hepatic or renal diseases ((ALT >3 times the upper limit of normal value, or end stage renal disease on dialysis or eGFR <30 mL/min/1.73 m2, or serum creatinine >2.5 mg/dl [>221 μmol/L])
- History of large atherosclerotic cerebral infarction or hemorrhagic stroke (not including lacunar infarction and transient ischemic attack [TIA])
- Hospitalization for myocardial infarction within last 6 months; Coronary revascularization (PCI or CABG) within last 12 months; Planned for PCI or CABG in the next 12 months.
- Sustained atrial fibrillation or arrhythmias at recruitment disturbing the electronic BP measurement.
- NYHA class III-IV heart failure; Hospitalization for chronic heart failure exacerbation within last 6 months.
- Severe valvular diseases; Potential for surgery or percutaneous valve replacement within the study period.
- Dilated cardiomyopathy; Hypertrophic cardiomyopathy; Rheumatic heart disease; Congenital heart disease.
- Other severe diseases influencing the entry or survival of participants, such as malignant tumor or acquired immune deficiency syndrome.
- Cognitive impairment or severe neuropsychiatric comorbidities who are incapable of providing their own informed consent.
- Participants preparing for or under pregnancy and/or lactation.
- Other conditions inappropriate for recruitment according to the investigators.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: FMT capsules
Intervention: FMT capsules containing extensively screened donor stool.
FMT capsules will be orally taken on Day 1, Day 7 (Week 1) and Day 14 (Week 2).
|
Intervention: FMT capsules containing extensively screened donor stool.
|
PLACEBO_COMPARATOR: Placebo capsules
Intervention: Placebo capsules that do not contain donor stool or any active drug.
Placebo capsules will be orally taken on Day 1, Day 7 (Week 1) and Day 14 (Week 2).
|
Intervention: Placebo capsules that do not contain donor stool or any active drug.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change for Office Systolic Blood Pressure (SBP)
Time Frame: From baseline to Day 30
|
Change for Office Systolic Blood Pressure (SBP)
|
From baseline to Day 30
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants with Adverse Events (AEs) as a Measure of Safety
Time Frame: All AEs over 3 months
|
Number of Participants with Adverse Events (AEs) as a Measure of Safety
|
All AEs over 3 months
|
Change for Office SBP
Time Frame: Baseline, Day 7, Day 14, Day 30, Day 60, Day 90
|
Change for Office SDBP
|
Baseline, Day 7, Day 14, Day 30, Day 60, Day 90
|
Change for Office Diastolic Blood Pressure (DBP)
Time Frame: Baseline, Day 7, Day 14, Day 30, Day 60, Day 90
|
Change for Office Diastolic Blood Pressure (DBP)
|
Baseline, Day 7, Day 14, Day 30, Day 60, Day 90
|
Change for Home Systolic Blood Pressure (SBP)
Time Frame: Baseline, Day 7, Day 14, Day 30, Day 60, Day 90
|
Change for Home Systolic Blood Pressure (SBP)
|
Baseline, Day 7, Day 14, Day 30, Day 60, Day 90
|
Change for Home Diastolic Blood Pressure (DBP)
Time Frame: Baseline, Day 7, Day 14, Day 30, Day 60, Day 90
|
Change for Home Diastolic Blood Pressure (DBP)
|
Baseline, Day 7, Day 14, Day 30, Day 60, Day 90
|
Change for average SBP via 24-hour Ambulatory BP Monitoring
Time Frame: Baseline, Day 30, Day 90
|
Change for average SBP via 24-hour Ambulatory BP Monitoring
|
Baseline, Day 30, Day 90
|
Change for average DBP via 24-hour Ambulatory BP Monitoring
Time Frame: Baseline, Day 30, Day 90
|
Change for average DBP via 24-hour Ambulatory BP Monitoring
|
Baseline, Day 30, Day 90
|
Change for daytime average SBP via 24-hour Ambulatory BP Monitoring
Time Frame: Baseline, Day 30, Day 90
|
Change for daytime average SBP via 24-hour Ambulatory BP Monitoring
|
Baseline, Day 30, Day 90
|
Change for daytime average DBP via 24-hour Ambulatory BP Monitoring
Time Frame: Baseline, Day 30, Day 90
|
Change for daytime average DBP via 24-hour Ambulatory BP Monitoring
|
Baseline, Day 30, Day 90
|
Change for nightime average SBP via 24-hour Ambulatory BP Monitoring
Time Frame: Baseline, Day 30, Day 90
|
Change for nightime average SBP via 24-hour Ambulatory BP Monitoring
|
Baseline, Day 30, Day 90
|
Change for nightime average DBP via 24-hour Ambulatory BP Monitoring
Time Frame: Baseline, Day 30, Day 90
|
Change for nightime average DBP via 24-hour Ambulatory BP Monitoring
|
Baseline, Day 30, Day 90
|
Change for Ankle-Brachial Blood Pressure Index(ABI)
Time Frame: Baseline, Day 90
|
Change for ABI as an objective measurement of arterial insufficiency based on the ratio of ankle systolic pressure to brachial systolic pressure.
|
Baseline, Day 90
|
Changes in Intestinal Microbiota Composition Pre- and Post-intervention via Metagenomic Analysis
Time Frame: Baseline, Day 7, Day 14, Day 30, Day 60, Day 90
|
Changes in Intestinal Microbiota Composition Pre- and Post-intervention (FMT or Placebo) via Metagenomic Analysis, stratified by:
|
Baseline, Day 7, Day 14, Day 30, Day 60, Day 90
|
Changes in Intestinal Microbiota Function Pre- and Post-intervention via Metagenomic Analysis
Time Frame: Baseline, Day 7, Day 14, Day 30, Day 60, Day 90
|
Changes in Intestinal Microbiota Function Pre- and Post-intervention (FMT or Placebo) via Metagenomic Analysis, stratified by:
|
Baseline, Day 7, Day 14, Day 30, Day 60, Day 90
|
Durability of Engraftment of Donor Microbiome Following FMT
Time Frame: Baseline, Day 7, Day 14, Day 30, Day 60, Day 90
|
Durability of engraftment of donor microbiome following FMT, measured by similarity comparison of intestinal microbiota composition between donor and recipient
|
Baseline, Day 7, Day 14, Day 30, Day 60, Day 90
|
Changes in Intestinal Metabolite Composition Pre- and Post-intervention via Metabolomic Analysis
Time Frame: Baseline, Day 7, Day 14, Day 30, Day 60, Day 90
|
Changes in Intestinal Metabolite Composition Pre- and Post-intervention (FMT or Placebo) via Metabolomic Analysis, stratified by:
|
Baseline, Day 7, Day 14, Day 30, Day 60, Day 90
|
Changes in Serum Metabolite Composition Pre- and Post-intervention via Metabolomic Analysis
Time Frame: Baseline, Day 7, Day 14, Day 30, Day 60, Day 90
|
Changes in Serum Metabolite Composition Pre- and Post-intervention (FMT or Placebo) via Metabolomic Analysis, stratified by:
|
Baseline, Day 7, Day 14, Day 30, Day 60, Day 90
|
Change for Fasting Blood Glucose Level
Time Frame: Baseline, Day 90
|
Change for Fasting Blood Glucose Level
|
Baseline, Day 90
|
Change for Blood Lipid Level (Total Cholesterol, Total Triglyceride, Low Density Lipoprotein Cholesterol, High Density Lipoprotein Cholesterol)
Time Frame: Baseline, Day 90
|
Change for Blood Lipid Level (Total Cholesterol, Total Triglyceride, Low Density Lipoprotein Cholesterol, High Density Lipoprotein Cholesterol)
|
Baseline, Day 90
|
Change for Body Mass Index
Time Frame: Baseline, Day 90
|
Change for Body Mass Index
|
Baseline, Day 90
|
Collaborators and Investigators
Publications and helpful links
General Publications
- Li J, Zhao F, Wang Y, Chen J, Tao J, Tian G, Wu S, Liu W, Cui Q, Geng B, Zhang W, Weldon R, Auguste K, Yang L, Liu X, Chen L, Yang X, Zhu B, Cai J. Gut microbiota dysbiosis contributes to the development of hypertension. Microbiome. 2017 Feb 1;5(1):14. doi: 10.1186/s40168-016-0222-x.
- Cammarota G, Ianiro G, Tilg H, Rajilic-Stojanovic M, Kump P, Satokari R, Sokol H, Arkkila P, Pintus C, Hart A, Segal J, Aloi M, Masucci L, Molinaro A, Scaldaferri F, Gasbarrini G, Lopez-Sanroman A, Link A, de Groot P, de Vos WM, Hogenauer C, Malfertheiner P, Mattila E, Milosavljevic T, Nieuwdorp M, Sanguinetti M, Simren M, Gasbarrini A; European FMT Working Group. European consensus conference on faecal microbiota transplantation in clinical practice. Gut. 2017 Apr;66(4):569-580. doi: 10.1136/gutjnl-2016-313017. Epub 2017 Jan 13.
- Translating Microbiome Research into Therapies: The Path Ahead. Cell. 2020 Apr 2;181(1):20-21. doi: 10.1016/j.cell.2020.03.009. No abstract available.
- Fan L, Ren J, Chen Y, Wang Y, Guo Z, Bu P, Yang J, Ma W, Zhu B, Zhao Y, Cai J. Effect of fecal microbiota transplantation on primary hypertension and the underlying mechanism of gut microbiome restoration: protocol of a randomized, blinded, placebo-controlled study. Trials. 2022 Feb 24;23(1):178. doi: 10.1186/s13063-022-06086-2.
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2017-GZ10 (Part I)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertension
-
National Taiwan University Hospital Hsin-Chu BranchRecruitingHypertension,Essential | Hypertension, MaskedTaiwan
-
University of Alabama at BirminghamTroy UniversityCompletedHypertension | Hypertension, Resistant to Conventional Therapy | Uncontrolled Hypertension | Hypertension, White CoatUnited States
-
BayerCompletedPrimary HypertensionChina
-
Addpharma Inc.Completed
-
Columbia UniversityAgency for Healthcare Research and Quality (AHRQ)Active, not recruitingWhite Coat Hypertension | Hypertension,EssentialUnited States
-
Universidade Federal de Santa MariaCompletedHealthy Volunteers | Hypertension, EssentialBrazil
-
Sulaiman AlRajhi CollegesUnknownHypertension, Essential | β-hydroxybutyrate
-
Sheffield Teaching Hospitals NHS Foundation TrustUniversity of SheffieldCompletedIdiopathic Pulmonary Arterial Hypertension | Chronic Thromboembolic Pulmonary HypertensionUnited Kingdom
-
China Academy of Chinese Medical SciencesGuang'anmen Hospital of China Academy of Chinese Medical SciencesCompletedHypertension, Resistant to Conventional Therapy | Primary HypertensionChina
Clinical Trials on FMT capsules
-
Aleris-Hamlet Hospitaler KøbenhavnUniversity of Aarhus; Hvidovre University HospitalCompletedIrritable Bowel SyndromeDenmark
-
Chinese Academy of Medical Sciences, Fuwai HospitalNot yet recruiting
-
Massachusetts General HospitalCompleted
-
Chinese Academy of Medical Sciences, Fuwai HospitalNot yet recruiting
-
University of CalgaryCumming school of medicine; The W. Garfield Westin FoundationRecruitingDepression | Treatment Resistant DepressionCanada
-
Thammasat UniversityRecruitingIrritable Bowel SyndromeThailand
-
Alice Højer ChristensenCompleted
-
Montefiore Medical CenterCompletedIrritable Bowel SyndromeUnited States
-
Xiangyu KongNot yet recruitingAdvanced Gastric CancerChina
-
Jean-Pierre RoutySt. Joseph's Health Care LondonNot yet recruiting